OBJECTIVE: The mammalian target of rapamycin (mTOR) pathway, an important regulator of multiple cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. It has achieved considerable importance. This study was conducted to determine the status of the mTOR pathway in human hepatocellular carcinoma (HCC) and to investigate its relationship with the prognosis of HCC. METHODS: PTEN, pAkt, p27, and pS6 expression in cryo-sections gathered from 528 cases with HCC by the method of immunohistochemistry. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of HCC. RESULTS: The mTOR pathway was more significantly altered in high-grade tumors, and tumors with poor prognostic features. Especially, pAkt and cytoplasmic p27 expression showed the strongest associations with pathological parameters of HCC. Statistical analysis showed that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different overall survival rates relative to those not expressing these proteins. Cox multi-factor analysis showed that tumor differentiation (P = 0.006), vascular invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC. CONCLUSION: Expression of the mTOR pathway components, which are related with the transferability and invasive capacity of HCC cells, may be used as prognostic indicators in HCC.
OBJECTIVE: The mammalian target of rapamycin (mTOR) pathway, an important regulator of multiple cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. It has achieved considerable importance. This study was conducted to determine the status of the mTOR pathway in humanhepatocellular carcinoma (HCC) and to investigate its relationship with the prognosis of HCC. METHODS:PTEN, pAkt, p27, and pS6 expression in cryo-sections gathered from 528 cases with HCC by the method of immunohistochemistry. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of HCC. RESULTS: The mTOR pathway was more significantly altered in high-grade tumors, and tumors with poor prognostic features. Especially, pAkt and cytoplasmic p27 expression showed the strongest associations with pathological parameters of HCC. Statistical analysis showed that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different overall survival rates relative to those not expressing these proteins. Cox multi-factor analysis showed that tumor differentiation (P = 0.006), vascular invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC. CONCLUSION: Expression of the mTOR pathway components, which are related with the transferability and invasive capacity of HCC cells, may be used as prognostic indicators in HCC.
Authors: M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Reuben J Shaw; Nabeel Bardeesy; Brendan D Manning; Lyle Lopez; Monica Kosmatka; Ronald A DePinho; Lewis C Cantley Journal: Cancer Cell Date: 2004-07 Impact factor: 31.743
Authors: Y Kurozawa; I Ogimoto; A Shibata; T Nose; T Yoshimura; H Suzuki; R Sakata; Y Fujita; S Ichikawa; N Iwai; A Tamakoshi Journal: Br J Cancer Date: 2005-09-05 Impact factor: 7.640
Authors: Yun-Yong Park; Bo Hwa Sohn; Randy L Johnson; Myoung-Hee Kang; Sang Bae Kim; Jae-Jun Shim; Lingegowda S Mangala; Ji Hoon Kim; Jeong Eun Yoo; Cristian Rodriguez-Aguayo; Sunila Pradeep; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Woojin Jeong; Inn Sun Park; Young Nyun Park; Anil K Sood; Gordon B Mills; Ju-Seog Lee Journal: Hepatology Date: 2015-11-26 Impact factor: 17.425
Authors: Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden Journal: Mol Cancer Ther Date: 2016-08-05 Impact factor: 6.261
Authors: Rosa H Jimenez; Joan M Boylan; Ju-Seog Lee; Mirko Francesconi; Gastone Castellani; Jennifer A Sanders; Philip A Gruppuso Journal: PLoS One Date: 2009-10-09 Impact factor: 3.240